ROSE Zur Rose Group AG

EQS-News: Zur Rose and KPT together launch digital medicines assistant Medi+

EQS Group-News: Zur Rose Group AG / Key word(s): Alliance
Zur Rose and KPT together launch digital medicines assistant Medi+

08.09.2020 / 07:00


Bern and Frauenfeld, 8 September 2020

Press release

Zur Rose and KPT together launch digital medicines assistant Medi+

The new Medi+ service from Zur Rose supports patients in taking and managing their medicines. Medi+ makes it easier to deal with medicines, increases patient safety and helps avoid incorrect medication and the associated follow-up costs. KPT is the first health insurer to offer its patients a digital medicines assistant - free of charge.

Anyone who has to take medicines regularly knows that keeping track of them is a challenge. KPT customers now have a new free digital medicines assistant available round the clock, helping them to stay even more in control of their medicines and when they take them. Medi+ offers a range of handy functions that make dealing with medicines easier and safer.

Medi+ generates a personal medicines summary. With the user's consent, all medicines settled through KPT are displayed in the summary; others can easily be included on the list using a scan function. The summary also shows medicines already ordered from Zur Rose and prescriptions that have been submitted. So users of Medi+ always have an up-to-date summary of all the medicines they need to take - whether they are at home, or travelling. The application can also create a schedule of when medicines should be taken, with a reminder function. Follow-up online orders of prescription drugs at Zur Rose are easy, safe and economical with Medi+. But you don't have to buy your medicines from Zur Rose to use the application: people who are insured with KPT are at liberty to get their medicines from the doctor or from a pharmacy of their choice.

KPT CEO Reto Egloff sees great potential in the digital networking: "Medi+ makes it simpler for our customers to deal with their medicines every day - not least thanks to the simple data transfer from the KPTnet customer portal. KPT is making another major step forward in cooperative digital networking in healthcare."

Walter Hess, Head of Zur Rose Switzerland, adds: "With Medi+ we are offering customers and patients a service that is safe and that permanently improves the supply of medicines. Together with KPT we are providing a further contribution to making the healthcare system more efficient and therefore cheaper."

 

Contact:

Pascale Ineichen, Head of Corporate Communications Zur Rose Suisse AG
Direct line 8 | Email

Beni Meier, Head of Corporate Communications KPT
Direct line 0 | Email:


Zur Rose Suisse AG

Zur Rose Suisse AG, a subsidiary of Zur Rose Group AG, is one of Switzerland's leading e-commerce pharmacies and medical wholesalers. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions. For further information please see zurrose.ch and zurrosegroup.com.

KPT

KPT Group is based in Bern and is one of the ten largest health insurers in Switzerland. Over 600 employees offer a wealth of personal advice and innovative solutions to around 410,000 customers.



End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: 4
Internet:
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1127211

 
End of News EQS Group News Service

1127211  08.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1127211&application_name=news&site_id=research_pool
EN
08/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zur Rose Group AG

 PRESS RELEASE

DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the ...

DocMorris AG / Key word(s): Development of Sales DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21 January 2025 Press release DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter All business divisions contribute to revenue growth in 2024 OTC revenues increase by 6.7 per cent in 2024 New Rx customers grew fivefold and Rx revenue up 16.6 per cent in the fourth quarter of 2024 TeleClinic with profitable doubling of revenue in 2024 Cash position of CHF 95 million...

 PRESS RELEASE

DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im v...

DocMorris AG / Schlagwort(e): Umsatzentwicklung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal 21.01.2025 / 06:58 CET/CEST Frauenfeld, 21. Januar 2025 Medienmitteilung DocMorris wächst 6.7 Prozent in 2024 und beschleunigt Rx-Wachstum im vierten Quartal Alle Geschäftsbereiche tragen zum Umsatzwachstum 2024 bei OTC-Umsatz 2024 erhöht sich um 6.7 Prozent Rx-Neukunden verfünffacht und Rx-Umsatz plus 16.6 Prozent im vierten Quartal 2024 TeleClinic mit profitabler Umsatzverdoppelung in 2024 Cashbestand von CHF 95 Mio. per Ende 2024 DocM...

 PRESS RELEASE

DocMorris beschleunigt Rx-Wachstum

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris beschleunigt Rx-Wachstum 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15. Oktober 2024 Medienmitteilung DocMorris beschleunigt Rx-Wachstum Rx-Umsatzwachstum von 12.2 Prozent im dritten Quartal Beschleunigung auf über 25 Prozent in den letzten Wochen Starke Zunahme der Rx-Neukunden OTC-Wachstum von 1.9 Prozent Pablo Ros Gomez wird neuer CTO Schliessung des Logistikstandorts in Halle (DE) Das E-Rezept-Geschäft von DocMorris nimmt weiter Fahrt auf: Im dritten Quartal 2024 wuchs der Aussenumsatz mit versch...

 PRESS RELEASE

DocMorris accelerates Rx growth

DocMorris AG / Key word(s): Quarterly / Interim Statement DocMorris accelerates Rx growth 15.10.2024 / 06:58 CET/CEST Frauenfeld, 15 October 2024 Press release DocMorris accelerates Rx growth Rx revenue growth of 12.2 per cent in the third quarter Acceleration to over 25 per cent in the last few weeks Strong increase in new Rx customers OTC growth of 1.9 per cent Pablo Ros Gomez becomes new CTO Closure of the logistics site in Halle (DE) DocMorris' e-prescription business continues to gain momentum: In the third quarter of 2024, external revenue of prescription med...

 PRESS RELEASE

DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukun...

DocMorris AG / Schlagwort(e): Quartals-/Zwischenmitteilung DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukunden, Marktanteil und Umsatz 11.07.2024 / 06:58 CET/CEST Frauenfeld, 11. Juli 2024 Medienmitteilung DocMorris mit beschleunigtem und signifikantem eRx-Wachstum bei Neukunden, Marktanteil und Umsatz Verdreifachung der Rx-Neukundenzahl seit CardLink-Einführung Verdoppelung und kontinuierliche Steigerung des eRx-Marktanteils seit Januar 2024 17 Prozent Umsatzwachstum rezeptpflichtiger Medikamente (Rx) gegenüber Vorquartal Seit Mitte April ist de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch